277 results on '"Martin, Clémence"'
Search Results
2. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
3. Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
4. CT imaging shows specific pancreatic abnormalities in persons with cystic fibrosis related diabetes
5. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
6. Asthma and COPD: distinct diseases or components of a continuum?
7. Contributors
8. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
9. The Changing Epidemiology of Cystic Fibrosis: The Implications for Adult Care
10. Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021
11. Beyond Kaftrio : mechanistic insights to maximize N1303K-CFTR rescue
12. “Il faut continuer à poser des questions” patient reported outcome measures in cystic fibrosis: An anthropological perspective
13. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function
14. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTRvariant: a real-world study
15. Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
16. Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
17. Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor
18. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint
19. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription
20. An automated computed tomography score for the cystic fibrosis lung
21. Impact of panelists’ experience on script concordance test scores of medical students
22. Chatbot-based serious games: A useful tool for training medical students? A randomized controlled trial
23. Pulmonary and Non-Pulmonary Sepsis Differentially Modulate Lung Immunity Towards Secondary Bacterial Pneumonia: A Critical Role for Alveolar Macrophages
24. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis
25. Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!
26. Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs
27. The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508delCFTRvariant
28. Neuraminidase is a host‐directed approach to regulate neutrophil responses in sepsis and COVID‐19
29. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis
30. Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin
31. CFTR Modulators: Current Status and Evolving Knowledge
32. Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis
33. Cytosolic PCNA interacts with S100A8 and controls an inflammatory subset of neutrophils in COVID-19
34. Specific circulating neutrophils subsets are present in clinically stable adults with cystic fibrosis and are further modulated by pulmonary exacerbations
35. Chapter 9 - Asthma and COPD: distinct diseases or components of a continuum?
36. Pulmonary and Nonpulmonary Sepsis Differentially Modulate Lung Immunity toward Secondary Bacterial Pneumonia: A Critical Role for Alveolar Macrophages.
37. Prognostic value of six minute walk test in cystic fibrosis adults
38. Cystic Fibrosis in 2021: “The Times They Are A-Changin”
39. Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test
40. Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
41. CFTR Modulators: Current Status and Evolving Knowledge.
42. Toll-Like Receptor 2 Deficiency Increases Resistance to Pseudomonas aeruginosa Pneumonia in the Setting of Sepsis-Induced Immune Dysfunction
43. CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
44. Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis
45. Change in Lung Function After Initiation of Elexacaftor-tezacaftor-ivacaftor: Do Not Forget Anatomy!
46. Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France
47. Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension
48. Targeting Mucus Hypersecretion: New Therapeutic Opportunities for COPD?
49. Intrapulmonary lymphoid neogenesis induced by prolonged bacterial airway infection in mice: PO.081
50. Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution in Pseudomonas aeruginosa Infection
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.